Evaluation of the utility of Abbott RealTime CMV in monitoring CMV infection of advanced cell-mediated immune deficiency patients by HIV infection

Evaluation of the utility of Abbott RealTime CMV in monitoring CMV infection of advanced cell-mediated immune deficiency patients by HIV infection - Abbott RealTime CMV Domestic Clinical Performance Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036829

Enrollment

Registered

2019-05-24

Start date

2017-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human immunodeficiency virus infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults of age 20 or older Patients diagnosed with HIV infection Suspected to be immune deficiency collected specimen after January 2014 (only apply for stored specimen) Consent form obtained

Exclusion criteria

Exclusion criteria: Patients who may be unable to make the follow-up hospital visits Blood collection tube (BCT) other than EDTA BCT were used during blood collection

Design outcomes

Primary

Measure	Time frame
Sensitivity and specificity in the detection of CMV infection using Abbott RealTime CMV (when antigenemia is a standard method)	—

Countries

Japan

Contacts

Public ContactYutaka Seki

Abbott Japan Co., Ltd. Molecular Division

yutaka.seki@abbott.com03-4555-1099

Outcome results